Hepatocellular Carcinoma News and Research

RSS
Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Understanding HCV disease progression rates among PWID

Understanding HCV disease progression rates among PWID

Inhibition of FGFR3 receptor could be a new way of treating patients with liver cell cancer

Inhibition of FGFR3 receptor could be a new way of treating patients with liver cell cancer

New DNA analysis may guide personalized management of hepatocellular carcinoma

New DNA analysis may guide personalized management of hepatocellular carcinoma

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Researchers identify new virus that plays role in rare type of liver cancer

Researchers identify new virus that plays role in rare type of liver cancer

New data shows liver cancer has significantly increased in Queensland since the mid-90s

New data shows liver cancer has significantly increased in Queensland since the mid-90s

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Study points to new treatment strategies for liver cancer

Study points to new treatment strategies for liver cancer

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

dlDNA marks progression of HBV-related liver disease

dlDNA marks progression of HBV-related liver disease

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.